Both SGLT2 inhibitors and GLP-1 agonists were associated with significantly lower all-cause mortality than that seen in controls (placebo or no treatment), while DPP-4 inhibitors were not, investigators found in the meta-analysis.
For that endpoint, SGLT2 inhibitors had an absolute risk difference of –1.0%, with a hazard ratio of 0.80, and GLP-1 agonists had an absolute RD of –0.6% and an HR of 0.88. By contrast, DPP-4 inhibitors had an absolute RD of 0.1% and an HR of 1.02, according to the published report.
Moreover, when compared with DPP-4 inhibitors, SGLT2 inhibitors and GLP-1 agonists were associated with reduced all-cause mortality, with an absolute risk difference of –0.9% and –0.5%, respectively, they found.
SGLT2 inhibitors and GLP-1 agonists also were significantly associated with lower cardiovascular mortality than controls were, while SGLT2 inhibitors were significantly associated with lower heart failure event rates versus those seen controls, they also found.